163 related articles for article (PubMed ID: 26974376)
1. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
Zhang H; Kang D; Huang B; Liu N; Zhao F; Zhan P; Liu X
Eur J Med Chem; 2016 May; 114():65-78. PubMed ID: 26974376
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
3. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
4. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.
Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
J Mol Graph Model; 2012 Sep; 38():123-36. PubMed ID: 23079643
[TBL] [Abstract][Full Text] [Related]
5. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
Peng D; Cao B; Zhou YJ; Long YQ
Eur J Med Chem; 2018 Apr; 149():148-169. PubMed ID: 29500940
[TBL] [Abstract][Full Text] [Related]
6. Structure-based development of antagonists for chemokine receptor CXCR4.
Zhang C; Hou T; Feng Z; Li Y
Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based small molecule CXCR4 ligands.
Narumi T; Tanaka T; Hashimoto C; Nomura W; Aikawa H; Sohma A; Itotani K; Kawamata M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem Lett; 2012 Jun; 22(12):4169-72. PubMed ID: 22579418
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists.
Shad MS; Claes S; Goffin E; Van Loy T; Schols D; De Jonghe S; Dehaen W
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684878
[TBL] [Abstract][Full Text] [Related]
9. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
10. Azamacrocyclic metal complexes as CXCR4 antagonists.
Tanaka T; Narumi T; Ozaki T; Sohma A; Ohashi N; Hashimoto C; Itotani K; Nomura W; Murakami T; Yamamoto N; Tamamura H
ChemMedChem; 2011 May; 6(5):834-9. PubMed ID: 21312334
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity.
Curreli F; Belov DS; Ramesh RR; Patel N; Altieri A; Kurkin AV; Debnath AK
Bioorg Med Chem; 2016 Nov; 24(22):5988-6003. PubMed ID: 27707628
[TBL] [Abstract][Full Text] [Related]
12. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
13. Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Das D; Maeda K; Hayashi Y; Gavande N; Desai DV; Chang SB; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 Apr; 59(4):1895-904. PubMed ID: 25583709
[TBL] [Abstract][Full Text] [Related]
14. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.
Choi WT; Yang Y; Xu Y; An J
Curr Top Med Chem; 2014; 14(13):1574-89. PubMed ID: 25159167
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
16. An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
Grande F; Giancotti G; Ioele G; Occhiuzzi MA; Garofalo A
Eur J Med Chem; 2017 Oct; 139():519-530. PubMed ID: 28826086
[TBL] [Abstract][Full Text] [Related]
17. Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.
Wilkinson RA; Pincus SH; Song K; Shepard JB; Weaver AJ; Labib ME; Teintze M
Bioorg Med Chem Lett; 2013 Apr; 23(7):2197-201. PubMed ID: 23434419
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.
Hu P; Wang X; Zhang B; Zhang S; Wang Q; Wang Z
ChemMedChem; 2014 May; 9(5):928-31. PubMed ID: 24474698
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists.
Emert-Sedlak LA; Loughran HM; Shi H; Kulp JL; Shu ST; Zhao J; Day BW; Wrobel JE; Reitz AB; Smithgall TE
Bioorg Med Chem Lett; 2016 Mar; 26(5):1480-1484. PubMed ID: 26852364
[TBL] [Abstract][Full Text] [Related]
20. Highly specific and sensitive pharmacophore model for identifying CXCR4 antagonists. Comparison with docking and shape-matching virtual screening performance.
Karaboga AS; Planesas JM; Petronin F; Teixidó J; Souchet M; Pérez-Nueno VI
J Chem Inf Model; 2013 May; 53(5):1043-56. PubMed ID: 23577723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
